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History of Medicine
Correspondence wit'h a pioneer,
Jiirgen Lehmann (1898 - 1989), producer of tl"le
first effective antituberculosis specific
H.DUBOVSKY
Summary
Correspondence between the author and Lehmann provided
evidence that the latter evolved the first effective antitubercu-
losis drug, para-aminosalicylic acid (PAS), contrary to
accepted belief that this honour belonged to Nobel Prize-
winner Selman A. Waksman for his production of strepto-
mycin. While both drugs appeared in 1943, successful animal
and clinical trials of PAS preceded those of streptomycin.
PAS has been discarded in modern treatment regimens
because of gastric side-effects, but was available at a critical
time to demonstrate the principle of multiple therapy in
prevention of bacterial resistance in tuberculosis therapy. It
probably saved streptomycin, which causes bacterial resis-
tance and clinical regression within 3 months when used
alone, from being discarded as an unsuitable drug of tem-
porary benefit and a public health hazard.
S AIr Med J 1991; 79: 48-50.
Medical opinion accepts the antibiotic streptomycin, produced
in the USA in 1943 by Se1man Waksman (1888-1973), as the
first effective antitubercu10sis drug. This earned him the
Nobe1 Prize in 1952. Evidence exists that priority of proved
clinical effectivity against tuberculosis should be accorded the
chemotherapeutic agent para-aminosalicylic acid (PAS)
evolved by }Urgen Lehmann of Sweden (Fig. 1). This claim
stands, despite the two drugs appearing in 1943 and. their
laboratory and clinical trials occurring nearly concurrently.
Initial disclosures
Lehmann's' first publication of his clinical trials on PAS
were published in The Lancet in 1946 as a preliminary com-
munication. He reported improvement with the local applica-
tion of PAS solutions in tuberculous fistulas, abscesses and
empyemas. The second part of his report was on PAS oral
therapy of 20 lung tuberculosis patients from March to October
1944. His findings were cautious but optimistic - fever
decrease, appetite improvement, weight gain and a raised
erythrocyte count. (Lehmann's disclosures occurred about 2
years after the trials.) He provided confirmatory evidence of
the early promise of the efficiency of PAS in an editorial2
published in 1964 as a historical review in American Review of
Respiracory Disease. This incluq.ed a presentation at a meeting
of the Scandinavian Physiological Society in 1946 of 82 patients
treated with·PAS by Vallentin and himself, as well as a survey
of Lehmann's publications in Diseases of the Chest in 1949 and
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Fig. 1. JOrgen Lehmann, 1898-1989.
in Tubercle in 1950 of the results of 378 patients treated with
PAS in six Swedish sanatoriums. He also referred to his
address at the Seventh Streptomycin Conference in Denver in
1949 in which he provided a state of the art of the Swedish
PAS experience including problems of PAS administration
and the determination of blood levels and bacterial resistance.
This was followed by a matched-ease comparison of effectivity
of 205 Swedish patients treated with PAS and 223 patients
treated with streptomycin by the Veterans' Administration of
the USA in 1947. PAS caused a slower regression of pulmonary
inflltrations radio10gically than streptomycin, but had a better
effect on lowering temperature and erythrocyte sedimentation
rate. Streptomycin had the advantage in weight gain and
sputum conversion but presented a serious problem of 8th
nerve toxicity of permanent deafness and vestibular damage.
PAS, despite large average oral doses of 14 gld caused no
toxic problems, only gastric irritation that improved by using
enteric coated granules instead of the tablets. Lehmann pointed
out that the major disadvantage of streptomycin was that 80%
of patients developed bacterial resistance within 3 - 4 months,
with clinical regression. With PAS this problem was negligible
and of slight degree occurring only after 3 - 6 months of
treatment.
Lehmann concluded his historical review by claiming, with
supporting dates, that the fIrst animal trials with PAS were
done 3 months before those of streptomycin and the fIrst
clinical trials of 20 patients nearly 8 months before, and said:
'In reality PAS was used before streptomycin and this is the
fIrst active chemical agent in the treatment of tuberculosis.'
The motivations for the discoveries of PAS and streptomycin
differed basically. The evolution of PAS was based on the
fmding by Bernheim3 in 1940 that salicylic acid stimulated the
oxygen uptake of the tubercle bacillus. Considering that closely
related compounds could have an inhibitory effect on the
metabolism of the bacillus, on the principle of competitive
antagonism, Bernheim tried 49 variations of salicylic acid and
related compounds between 1941 and 1943 without success.
Continuing this line of research, Lehmann achieved success
after more than 50 variations when he asked the Ferrosan
pharmaceutical fIrm in March 1943 to place an amino group in
the para position of the benzine ring of the salicylic acid
molecule, creating para-aminosalicyclic acid (PAS).
Although this synthesis proved difficult, with only 13 g
becoming available by December 1943, PAS was shown to
inhibit growth of Mycobacterium tuberculosis on culture. Mter
animal studies on infected rabbits and guinea-pigs showed
therapeutic response and lack of toxicity, the clinical trials
began in March 1944.
Contrasted with Lehmann's logical and continued line of
research, the role of Waksman in the production of strepto-
mycin could be considered sporadic and somewhat detached.
He was not a physician and, as professor of soil microbiology
at the small agricultural college of Rutgers, his primary concern
and life-long interest was the study and teaching of the role of
soil micro-organisms in the breakdown of plant and animal
residues in the maintenance of soil fertility. He used post-
graduate students to do the research, in interrupted periods,
which led to the discovery of streptomycin. This started in
1932 when the National Tuberculosis Association asked him to
investigate the fate of tuberculosis germs in the soil. Comroe4
states that streptomycin would have been discovered much
sooner had not Waksman missed several clues over the years;
particularly in 1935 when the poultry pathologist at Rutgers
asked him to identify an organism isolated from the throat of a
sick chicken, which had killed and replaced tubercle bacilli on
culture by contamination. This was streptomyces griseus from
which, in 1943, Waksman isolated streptomycin. Waksman
later admitted that he did not take advantage of this observation
being preoccupied with soil fertility studies. Even in January
1944 when his group published5 the cultural activity of the
recently discovered streptomycin against 22 pathogens,
including inhibition of growth of M. tuberculosis, the profound
signifIcance of a potential antibiotic effective against the
tubercle bacillus was not noted by the authors. Similarly, the
group's next paperli in August 1944 tested the activity of
streptomycin on mice infected with various Gram-negative
bacteria but not with M. tuberculosis. Streptomycin may have
been lost to tuberculosis treatment for many years had not
Feldman and Hinshaw of the Mayo Foundation, aware of
Waksman's antibiotic research and his limited facilities, and
seeking potential tuberculosis agents for animal research,
offered to do animal studies for him. From April 1944, when
Waksman supplied them with 10 g of streptomycin, subse-
quently supplemented by the Merck Co. who took over the
manufacture and patent rights, to September 1944, Feldman
and Hinshaw proved the effectiveness of streptomycin on
tuberculosis-infected guinea-pigs. The fIrst patient to receive
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streptomycin was a 21-year-old woman with advanced tubercu-
losis. She was treated with interrupted courses of streptomycin
by Dr K. Pfuetze at the Mineral Falls Sanatorium from
November 1944 to April 1945. She improved remarkably with
~est of the disease 2 years later. This good result contrasted
with the negative report by Hinshaw et al. 7 of an uncontrolled
study of 100 cases in 1946. They found streptomycin 'encou-
raging' but not recommended for patients 'making satisfactory
progress or likely to achieve arrest of their disease as a result of
conventional therapeutic methods'.
The correspondence
As an apparent injustice to Lehmann existed of lack of
recognition as the developer of the fIrst effective drug for
tuberculosis, the author wrote to the laboratory where Lehmann
had done his research for early data on PAS. A reply was
received from Lehmann who provided personal information
and comprehensive reprints. This started a correspondence
with Lehmann who was then 88 years old and did his own







Your letter to the Director of the Central Laboratory at Sahlgrens
Hospital was forwarded to me. It was the most remarkable letter I
have received for many years. You are the fIrst outside Sweden
who has paid attention to the fact that PAS was in clinical use
before streptomycin, eight months before. . . . Perhaps you
wonder why I published the fIrst paper on PAS so long after it
was taken in clinical use. The reason was that as Ferrosan, a small
company had not taken out a patent on PAS, I didn't dare to
publish the formula on PAS as other greater companies could take
over the production of PAS....
When Waksman, whom I met at international congress, had got
the Nobel Prize, I cabled congratulations to him. Two weeks later
I got a letter from him in which he mentioned that he expected
that we get the prize together. In the international literature very
little attention is paid to PAS and this has been very disappointing
to me as I have published papers in which I have pointed out that
PAS was the fIrst remedy effective against tuberculosis.... I have




Three more letters followed with more information enabling
the authorS to publish and send to Lehmann a comparative
study of the history of PAS and streptomycin. A reply was
received from his'wife on 12' August 1988 conveying thanks
from her husband who was unable to reply on account of
general debility. Another letter from her advised that Lehmann
passed away on 26 December 1989 in an institution for frail
care a few weeks short of his 92nd birthday.
jiirgen Lehmann
Lehmann's family had an academic background. His father
and grandfather,. respectively, held chairs in the history of
theology and in ophthalmology. His hobbies were art, painting
and music. He was born in Copenhagen and qualifIed in
medicine at the University of Lund. He started his academic
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career in 1920 and worked at various universities in Scandi-
navia, holding chairs in physiology, biochemistry and pharma-
cology. Enzymes and analytical methods were the main fields
of his research, and he carried out original studies in the use of
vitamin K in haemorrhage of the newborn, the estimation of
vitamin B I levels in the diagnosis of beri-beri, the use of
dicoumerol in thrombosis and the role of tryptophane defi-
ciency as a cause of psychosis. At the time of his discovery of
PAS, Lehmann was head of the laboratory of the Sahlgrenska
Hospital in GOteborg, Sweden.
The significance of PAS
The major contribution of PAS to tuberculosis therapy was
that it was available at a critical period to establish the
principle of multiple therapy in preventing bacterial resistance.
The British Medical Research Council,9 testing three concur-
rent groups on PAS alone, streptomycin alone and PAS and
streptomycin, felt obliged in 1949 to publish a preliminary
report of great importance; the combination of PAS and
streptomycin considerably reduced the risk of the development
of bacterial resistance to streptomycin. The CouncillO further
found, in 1955, that in including the recently discovered INH
in trials that while the combination streptomycin + INH was
more effective therapeutically than PAS + INH, the latter
combination was preferred, since it was more effective in
preventing bacterial resistance. It could be said that PAS
formed an important bridge of bacterial resistance prevention
between the discoveries of streptomycin in 1943 and INH in
1953. Without this link, streptomycin might have been dis-
carded as a drug of temporary benefit followed by clinical
decline and the emergence of the epidemiological hazard of
bacterial resistance of the tubercle bacillus. The combination
streptomycin +PAS + INH as 'triple therapy' became standard
effective ·treatment until about 1970, when PAS was replaced,
because it caused gastric irritation, by more convenient drugs.
Conclusion
Lehmann was hurt by lack of recognition as the discoverer
of the first effective antituberculosis specific. This could be
basically ascribed to lack of publicity due to his delay of 2
years in publishing his clinical trials. A contributory factor was
the small quantities of PAS made available in the early years
of its use due to the limited facilities of the Swedish manufac-
turing firm. In contrast, streptomycin was more freely available
at a corresponding period as manufacture was taken over by
the large Merck company. The ease of use of streptomycin as
an intramuscular injection in contrast with the gastric problems
of PAS favoured its acceptance. Birath11 provides an additional
reason for the delayed acceptance of PAS - the scepticism of
Swedish doctors in 1946 when the results were first made
known; they suspected that the beneficial effects were due to
salicylic acid's known antipyretic action rather than a specific
antituberculosis one.
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